Drug Information Related to Zometa
Back
01. Osteonecrosis of the Jaw. Zometa,Aredia,Fosamax linked to Jaw Bone Los...
Osteonecrosis of the
Jaw. Zometa,Aredia,and Fosamax are common drugs that have
been linked to the loss of jaw bone
These drugs are a type of drug known as bisphosphonates.
Recently a link has been found between bisphosphonates and a
serious bone disease called osteon...
02. Spinal Arthritis, Old Age is Not the Only Cause
For a lot of older people that are suffering from spinal arthritis feel very debilitated. Most of the people suffering from this disease are older, but there are some younger persons that are already have been struck by a mild form of spinal arthritis. This type of ar...
03. Information About Benefits of Narcotic Pain Reliever
Type of Drug:
Narcotic pain reliever combinations.
Uses:
To relieve moderate to severe pain.
Components of these combinations include:
Narcotic analgesics: Codeine, hydrocodone bitartrate, dihydrocodeine bitartrate, opium, oxycodone HCI, ...
04. Second Conviction of a Drug Trafficking Offense
If a defendant has been indicted by the federal government for a violation of the narcotics statute, 21 U.S.C. 841 (b), and he has a prior conviction for a drug offense, the penalties can become quite severe.
The mandatory penalties can double in prison time if a...
05. Drugs Used in Allergy
The word 'allergic' is often used loosely and has become almost a part of our general conversation. In a way it has become synonymous with 'dislike'. Many ailments which cannot be immediately diagnosed are incorrectly attributed to allergy. Infact, allergy is an unusu...
06. Primary Herpes Simplex Virus (HSV) Infection
Primary Herpes Simplex (HSV-I) type 1 produces the most common viral infection in the oral cavity. It most often occurs in children under 6 years of age but can involve older patients. In most children primary infection is sub-clinical (without clinical signs or sympt...
07. Philadelphia Lawyer's Analysis of Fosamax Lawsuits
Fosamax LawsuitsIn a December 13, 2004 press release, doctors at Long Island Jewish Medical Center (LIJ) announced that they had discovered a link between bisphosphonate drugs and osteonecrosis of the jaw (ONJ), or literally, death of the jaw bone tissue.Bisphosphonat...
08. Bone drug Zometa helps fight breast cancer spread - Free Online Librar...
A drug to prevent bone loss during breast cancer treatment also substantially cut the risk that the cancer would return, results that left doctors excited about a possible new way to fight the disease.It is the first large study to affirm wider anti-cancer hopes for Z...
09. Novartis Pharma Obtains Additional Approval for Its Proprietary ......
Tokyo, Japan, June 16, 2006 - (JCN) - Novartis Pharma has obtained additional approval for Neoral (cyclosporine), its proprietary immunosuppressant immunosuppressant /im·mu·no·sup·pres·sant/ (-sah-pres´ant) an agent capable of suppressing immune responses....
10. Dainippon Sumitomo Pharma Receives Approval for Antifungal Agent ......
Tokyo, Japan, Apr 21, 2006 - (JCN) - Dainippon Sumitomo Pharma announced on April 20 that it has received approval for AmBisome for Injection 50mg, a liposomal formulation of the antifungal 1. destructive to fungi, or suppressing their reproduction or growth; effecti...
11. Reuters Health News Summary - Free Online Library
Following is a summary of health news briefs compiled from
stories that have run separately and are available in full on
the file.
CORRECTED-Blood test may detect lung cancer in early stages CHICAGO (Reuters) - A simple blood test may be able to
detect lung cancer ...
12. Zometa OK'ed for one indication, Novartis tries for another | Drug ......
Days after Novartis received FDA approval to market Zometa (zoledronic acid for injection) as a hypercalcemia treatment, the drug company filed an additional indication for the drug. Novartis was cleared to market Zometa Aug. 20 for the treatment of hypercalcemia, a p...
13. Novartis' Zometa offers advance in bone complications of kidney cancer...
Swiss pharmaceutical major Novartis' bisphosphonate Zometa (zoledronic acid), already approved and marketed in over 60 countries including the USA for the prevention of skeletal-related events in patients with advanced malignancies involving bone, may also delay...
14. Long-term efficacy data on Novartis drug Zometa for broad range of ......
...
15. FDA grants priority review for Zometa in the treatment of a serious .....
M2 PRESSWIRE-23 October 2001-NOVARTIS: FDA grants priority review for Zometa in the treatment of a serious cancer complication (C)1994-2001 M2 COMMUNICATIONS LTD RDATE:23102001 Basel -- Novartis announced today that Zometa (zoledronic acid) has been designa...
16. Novartis files Zometa application.(with Food and Drug Administration ....
Novartis Pharmaceuticals Corp. has asked the FDA to market Zometa in the treatment of bone complications ...
...
17. Zoledronic acid (Zometa): bisphosphonate for prostate cancer/bone ......
Prostate cancer is most likely to metastasize to the bone. Approximately 50% to 70% of prostate cancer patients develop skeletal metastases and associated bone pain (Buckwalter & Brandser, 1997). Most men with advanced disease who die of prostate cancer have ...
18. Bone Drug Lowers Risk of Breast Cancer Recurrence | HealthDay | Find ....
A drug used to treat osteoporosis lowered the risk of breast cancer recurrence in premenopausal women with early breast cancer.
...
19. Update on osteonecrosis: what you need to know about bone death, and ....
You may have seen the term osteonecrosis in recent newspaper stories about the association between high doses of intravenous osteoporosis drugs called bisphosphonates and a rare form of bone death in the jaw. The reports may seem alarming, but the problem rarely affec...
20. Experts Compare Osteoporosis Drugs | HealthDay | Find Articles at BNET...
There's no proof that widely used bisphosphonate drugs are more effective than other treatments at preventing fractures in people with osteoporosis, says a U.S. Agency for Healthcare Research and Quality (AHRQ) report published online Monday in the journal Annals of Int...